Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1 and consolidated cash, cash equivalents and short-term investments of $350.1 million,2 as of December 31, 2022. Rapid advancement of PureTech’s Wholly Owned Pipeline, with four clinical stage therapeutic candidates, including LYT-100 (ongoing registration-enabling trial in IPF), LYT-300 (Phase 2 ready Read the full article...
The post PureTech Announces Annual Results for Year Ended December 31, 2022 first appeared on MJNews Network.
http://dlvr.it/SnCCnZ
No comments:
Post a Comment